Skip to main content

      TrendLens

      An in-depth look at the numbers that matter

      As the leading pharmacy benefit manager (PBM), our comprehensive approach to cost management focuses on impacting key drivers of drug spend. Through simplified pricing, flexible plan designs and member-focused utilization management, we help clients effectively manage drug spend and drive down drug trend.

      TrendLens takes a closer look at data points that demonstrate how we’re moving the needle and responding to key trends in the pharmacy benefits space.

      2024 Trend

       

      • 8.4%

        overall trend

      • 11.5%

        non-specialty trend

      • 5.5%

        specialty trend

      Clients that implemented cost strategies curbed GLP-1 spending

      The increased demand for GLP-1s is driving non-specialty trend, which continues to outpace specialty trend. With the impact to pharmacy spend, implementing cost management and member-focused support strategies is more important than ever. As our clients navigate the financial and clinical implications of this expanding therapy, we’re supporting them with flexible weight management programs, formulary options and other solutions.

      2024 Results:

      • 0% antidiabetics trend
      • Health plan clients with full program adoption saved 52%1
      • Employer clients with full program adoption saved 48%2
      • Net unit cost for insulin decreased 20%  

      Learn more about the rise of GLP-1s to improve metabolic health here.

      Trend insight

      GLP-1 spend drives nearly 60% of the non-specialty trend

      "We’re the only ones in the supply chain that are actively looking to negotiate the price of prescription drugs down.”

       

      Ed Devaney,

      EVP & President, CVS Caremark

      Leading the industry with transparent solutions

      Transparency is central to everything we do. We prioritize it in our interactions with clients and their members, recognizing its crucial role in building and maintaining long-term trust. There’s a significant and well-warranted focus on seeing how much medication costs – and understanding how health care dollars are spent. We’re moving the industry forward with new transparency solutions.

       

      Pie chart illustrating over 90% adoption of Caremark TrueCost. The chart visually represents the high percentage of users who have adopted the Caremark TrueCost program, with a large segment indicating the majority adoption rate.

      More than 90% of CVS Caremark’s clients already utilize 2 or more attributes of CVS Caremark TrueCost®, our acquisition-based pricing model3

      Pie chart illustrating over 90% adoption of Caremark TrueCost. The chart visually represents the high percentage of users who have adopted the Caremark TrueCost program, with a large segment indicating the majority adoption rate.

      Delivering exceptional member and client experiences

      We’re committed to providing simple, straightforward and personalized experiences, focusing on:

      • being proactive and supportive
      • making experiences easy and clear
      • helping members maximize their benefits and minimize costs

      86%

      of members paid $0 out-of-pocket for biosimilars

      98%

      overall client satisfaction

      97%

      client retention

      $7.26

      average out-of-pocket cost for 30-day supply

      • 1. Based on formulary, quantity limit and utilization management strategies

      • 2. Program adoption - Advanced Control Specialty Formulary, Exclusive Specialty, Specialty Guideline Management and PrudentRx

      • 3. S1017670425

       

      The source for data in this document is CVS Health Enterprise Analytics, unless otherwise noted. Adherence results may vary based upon a variety of factors such as plan design, demographics and programs adopted by the plan. Client-specific modeling available upon request. Savings will vary based upon a variety of factors including things such as plan design, demographics and programs implemented by the plan. CVS Health uses and shares data as allowed by applicable law, and by our agreements and our information firewall.​